Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 5Breast Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Stomach Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Tongue Neoplasms 1Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Endometrial Stromal 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Osteosarcoma 1Neoplasms, Plasma Cell 1Melanoma 1Lymphangioleiomyomatosis 1Lung Neoplasms 1Liver Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Fibrosarcoma 1Fallopian Tube Neoplasms 1

Interventions

carotuximab 2Methotrexate 2Leucovorin 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Dactinomycin 2Carboplatin 2Bevacizumab 2saracatinib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1etoposide phosphate 1cediranib 1Thiotepa 1Specimen Handling 1Second-Look Surgery 1Reoperation 1Radiotherapy 1Radiation 1Peripheral Blood Stem Cell Transplantation 1Pemetrexed 1Paclitaxel 1Mesna 1Magnetic Resonance Spectroscopy 1Filgrastim 1Drug Therapy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Choriocarcinoma × saracatinib × Clear all
NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡